Sodium Zirconium Cyclosilicate

  • TRADE NAME: Lokelma (AstraZeneca)
  • INDICATIONS: hyperkalemia
  • CLASS: Potassium binder

FDA APPROVAL DATE: 05/18/2018

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: N/A
maternal use is not expected to result in fetal exposure to the drug

Our database has 5 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
GASTROINTESTINAL/HEPATIC
ENDOCRINE/METABOLIC
GENITOURINARY


Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric